The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer

Prodromidou, Anastasia; Andreakos, Panagiotis; Kazakos, C.; Vlachos, Dimitrios‐Efthymios; Perrea, Despina; Pergialiotis, Vasilios

doi:10.1007/s00011-017-1026-6

Cited by 51 publications

(46 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our study is the first to provide data for patients from Northeast China with advanced EOC. Other published studies analyzing the data of foreign patients outside China had the consistent conclusion with us [4, 15, 16, 23-25]. …”

Section: Discussionsupporting

confidence: 70%

Neutrophil-to-Lymphocyte Ratio and Platelet Count Predict Long-Term Outcome of Stage IIIC Epithelial Ovarian Cancer

Zhou

Wang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Prognostic value of neutrophil-to-lymphocyte ratio (NLR) and platelet count (PC) in patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC epithelial ovarian cancer (EOC) is controversial. Methods: A total of 370 stage IIIC EOC patients who underwent primary debulking surgery (PDS) at the Department of Gynecology of Liaoning Cancer Hospital and Institute between January 2003 and August 2016 and had full information were involved. Patients were stratified into a high NLR (H-NLR) group versus a low NLR (L-NLR) group and a high PC (H-PC) group versus a low PC (L-PC) group according to cutoff values calculated through receiver operating characteristic (ROC) curves. Prognostic values of NLR and PC for progression-free survival (PFS) and overall survival (OS) were assessed. Results: We identified the optimal cut-off value of 3.08 for NLR and 289.5*10⁹/L for PC. The median PFS and OS of the patients with H-NLR were shorter than L-NLR (PFS: 16.9 months vs. 19.5 months, hazard ratio [HR] 1.3, 95% confidence interval [CI] 1.03–1.63, P = 0.022; OS: 33.5 months vs. 46.8 months, HR 1.3, 95% CI 1.01–1.66, P = 0.001). The median PFS and OS of the patients with H-PC were shorter than L-PC (PFS: 15.3 months vs. 21.6 months, HR 1.3, 95% CI 1.04–1.63, P < 0.001; OS: 37.3 months vs. 46.1 months, HR 1.14, 95% CI 0.89–1.46, P = 0.306). Conclusions: H-NLR and H-PC could predict poor long-term outcome of patients with FIGO stage III EOC.

show abstract

Section: Discussionsupporting

confidence: 70%

Neutrophil-to-Lymphocyte Ratio and Platelet Count Predict Long-Term Outcome of Stage IIIC Epithelial Ovarian Cancer

Zhou

Wang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…They commented on the limited sensitivity and specificity, that might be limiting its use only as adjunct biomarkers for the detection of the disease. 15 The Elevated pretreatment PLR, as referred to in our work , could be an unfavorable prognostic factor for clinical outcomes in patients with ovarian cancer, which was also concluded by Chuan T et al 16 Yildrim MA et al reported no significant difference between early and late stage disease regarding platelet count, lymphocytic count and PLR. 17 The results of Kokcu A et al reported a significant elevation of both platelet counts, and PLR as well as a significant direct correlations with CA125, and a significant rise of PLR with advanced stage disease.…”

supporting

confidence: 84%

Using platelet-to-lymphocyte ratio as a diagnostic marker in malignant ovarian tumors

Agameya¹,

Labib²,

Moiety³

2018

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

Background: Ovarian malignancy, is the fifth global fatal disease for women, and the most common cause of death in Gynecological cancer. Objective was to evaluate any diagnostic role of Platelet-to-lymphocyte ratio in epithelial ovarian tumors.Methods: A prospective analysis, over 1 year; (October 2016 to October 2017). Setting: University hospital’s Gynaecological oncology centre. Subjects & Methodology: A total of 36 patients with epithelial ovarian tumors, not under any adjuvant therapy and negative for any other malignancy, or any blood diseases causing blood count changes. All subjects underwent preoperative assessment of CA125 and Platelet-to-lymphocyte ratio (PLR), followed by a staging laparotomy and the appropriate management according to the standard protocols. Postoperative histopathological confirmation of the disease type, stage and grade was done for all cases.Results: (77.8%) of the patients had early stage disease while (22.2%) had advanced stage. Neither mean platelet, lymphocytic counts, nor PLR express any significant difference between early and late stage disease. CA 125 levels, however changed significantly in advanced stages. PLR showed a statistically significant difference between the three stages of the disease (P=0.007). There was a positive correlation between PLR and CA125 (r=0.184 and P=0.283).Conclusions: PLR rise significantly with tumor stages and correlates significantly with CA125. No significant change in PLR values with tumor type or grade. PLR might be a potential diagnostic / prognostic marker of ovarian epithelial cancer.

show abstract

“…Elevated platelet counts and thrombocytosis have been shown to actively affect tumor growth and metastasis in ovarian cancer . By contrast, the few studies that have investigated the use of platelet count or PLR in diagnosing endometriosis did not find a significant relationship .…”

Section: Discussionmentioning

confidence: 87%

“…Indicators of local and systemic inflammatory response, such as WBCs, neutrophils, and lymphocytes have been proposed as key factors in the pathogenesis of both ovarian cancer and endometriosis. Reportedly, NLR or NLR combined with CA125, can be more effective in diagnosing cancer or endometriosis as compared with CA125 alone . Cho et al .…”

Section: Discussionmentioning

confidence: 99%

Diagnostic value of serum D‐dimer,CA125, and neutrophil‐to‐lymphocyte ratio in differentiating ovarian cancer and endometriosis

Chen

Wang

Shu

et al. 2019

Intl J Gynecology & Obste

View full text Add to dashboard Cite

Objective: To assess the utility of hematologic, inflammatory, and immunologic biomarkers for differentiating between ovarian cancer and endometriosis.Methods: Data were retrospectively reviewed from women diagnosed with ovarian cancer and endometriosis after ovarian cyst surgery in Zhejiang, China, 2014 Serologic and hematologic biomarkers, including white blood cell count, lymphocyte count, neutrophil count, red blood cell count, hemoglobin, platelets, and D-dimer, albumin, globulin, cancer antigen 125 (CA125) and CA199 serum levels recorded preoperatively were assessed by ROC curve and logistic regression analysis. Results:Overall, 49 women were diagnosed with ovarian cancer and 192 with endometriosis. For predicting ovarian cancer, the area under the curve (AUC) was 0.96 (95% confidence interval [CI], 0.94-0.99); sensitivity, 93.2%; specificity, 87.5%) for log(Ddimer), 0.95 (95% CI, 0.91-0.98; sensitivity, 81.3%; specificity, 96.3%) for log(CA125), and 0.92 (95% CI, 0.86-0.98; sensitivity, 92.6%; specificity, 79.2%) for neutrophil-tolymphocyte ratio (NLR). The AUC for the combination of D-dimer, NLR, and CA125 was 0.96 (95% CI, 0.94-0.99; sensitivity, 91.6%; specificity, 89.6%).Conclusion: Serum D-dimer, NLR, and CA125 were found to be potential diagnostic factors for ovarian cancer. Combined measurement of D-dimer, NLR, and CA125 might offer a convenient screening method.

show abstract

The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer

Cited by 51 publications

References 49 publications

Neutrophil-to-Lymphocyte Ratio and Platelet Count Predict Long-Term Outcome of Stage IIIC Epithelial Ovarian Cancer

Neutrophil-to-Lymphocyte Ratio and Platelet Count Predict Long-Term Outcome of Stage IIIC Epithelial Ovarian Cancer

Using platelet-to-lymphocyte ratio as a diagnostic marker in malignant ovarian tumors

Diagnostic value of serum D‐dimer,CA125, and neutrophil‐to‐lymphocyte ratio in differentiating ovarian cancer and endometriosis

Contact Info

Product

Resources

About